Literature DB >> 12220628

Identification of a dominant self-ligand bound to three HLA B44 alleles and the preliminary crystallographic analysis of recombinant forms of each complex.

Whitney Macdonald1, David S Williams, Craig S Clements, Jeffery J Gorman, Lars Kjer-Nielsen, Andrew G Brooks, James McCluskey, Jamie Rossjohn, Anthony W Purcell.   

Abstract

A naturally processed and presented ligand that is shared by human leukocyte antigen (HLA) B*4402, B*4403 and B*4405 molecules has been identified in peptides isolated from immunoaffinity purified HLA B44 complexes. This peptide derived from HLA DPalpha residues 46-54, an endogenous product of HLA DP expressed in the cell line Hmy2.C1R, is a prominent peptide in the mass spectra of species isolated as bound peptides from each allele when the three HLA B44 subtypes were introduced as transfected gene products. Recombinant truncated forms of HLA B*4405(1-276), HLA B*4403(1-276), HLA B*4402(1-276) and beta(2)-microglobulin have been prepared as inclusion bodies in Escherichia coli and refolded in the presence of the DPalpha(46-54) peptide and purified by a combination of size exclusion and anion exchange chromatography. This material was determined to be correctly folded based on detection of a conformational epitope recognized by the W6/32 monoclonal antibody. Large, plate-like crystals of the three complexes were produced using polyethylene glycol as the precipitant. All the crystals belong to the space group P2(1)2(1)2(1) with unit cell dimensions of approximately a=51, b=82, c=110 A. The crystals of three B44/DPalpha complexes diffracted to a resolution of 1.9 A or better. For the first time, using this natural, high abundance ligand of the HLA B44 molecules we have successfully expressed and refolded the three HLA B44 molecules and produced crystals amenable to structural studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12220628     DOI: 10.1016/s0014-5793(02)03149-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  The impact of human leukocyte antigen (HLA) micropolymorphism on ligand specificity within the HLA-B*41 allotypic family.

Authors:  Christina Bade-Döding; Alex Theodossis; Stephanie Gras; Lars Kjer-Nielsen; Britta Eiz-Vesper; Axel Seltsam; Trevor Huyton; Jamie Rossjohn; James McCluskey; Rainer Blasczyk
Journal:  Haematologica       Date:  2010-10-07       Impact factor: 9.941

2.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.

Authors:  Patricia T Illing; Julian P Vivian; Nadine L Dudek; Lyudmila Kostenko; Zhenjun Chen; Mandvi Bharadwaj; John J Miles; Lars Kjer-Nielsen; Stephanie Gras; Nicholas A Williamson; Scott R Burrows; Anthony W Purcell; Jamie Rossjohn; James McCluskey
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

3.  The human leukocyte antigen-presented ligandome of B lymphocytes.

Authors:  Chopie Hassan; Michel G D Kester; Arnoud H de Ru; Pleun Hombrink; Jan Wouter Drijfhout; Harm Nijveen; Jack A M Leunissen; Mirjam H M Heemskerk; J H Frederik Falkenburg; Peter A van Veelen
Journal:  Mol Cell Proteomics       Date:  2013-03-12       Impact factor: 5.911

4.  Distinct assembly profiles of HLA-B molecules.

Authors:  Syed Monem Rizvi; Nasir Salam; Jie Geng; Ying Qi; Jay H Bream; Priya Duggal; Shehnaz K Hussain; Jeremy Martinson; Steven M Wolinsky; Mary Carrington; Malini Raghavan
Journal:  J Immunol       Date:  2014-04-30       Impact factor: 5.422

5.  Allelic polymorphism in the T cell receptor and its impact on immune responses.

Authors:  Stephanie Gras; Zhenjun Chen; John J Miles; Yu Chih Liu; Melissa J Bell; Lucy C Sullivan; Lars Kjer-Nielsen; Rebekah M Brennan; Jacqueline M Burrows; Michelle A Neller; Rajiv Khanna; Anthony W Purcell; Andrew G Brooks; James McCluskey; Jamie Rossjohn; Scott R Burrows
Journal:  J Exp Med       Date:  2010-06-21       Impact factor: 14.307

6.  Complete modification of TCR specificity and repertoire selection does not perturb a CD8+ T cell immunodominance hierarchy.

Authors:  Katherine Kedzierska; Carole Guillonneau; Stephanie Gras; Lauren A Hatton; Richard Webby; Anthony W Purcell; Jamie Rossjohn; Peter C Doherty; Stephen J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-01       Impact factor: 11.205

7.  Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold.

Authors:  Sophie A Valkenburg; Stephanie Gras; Carole Guillonneau; Nicole L La Gruta; Paul G Thomas; Anthony W Purcell; Jamie Rossjohn; Peter C Doherty; Stephen J Turner; Katherine Kedzierska
Journal:  PLoS Pathog       Date:  2010-08-12       Impact factor: 6.823

8.  The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation.

Authors:  Fleur E Tynan; Diah Elhassen; Anthony W Purcell; Jacqueline M Burrows; Natalie A Borg; John J Miles; Nicholas A Williamson; Kate J Green; Judy Tellam; Lars Kjer-Nielsen; James McCluskey; Jamie Rossjohn; Scott R Burrows
Journal:  J Exp Med       Date:  2005-11-07       Impact factor: 14.307

9.  Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition.

Authors:  Julia K Archbold; Whitney A Macdonald; Stephanie Gras; Lauren K Ely; John J Miles; Melissa J Bell; Rebekah M Brennan; Travis Beddoe; Matthew C J Wilce; Craig S Clements; Anthony W Purcell; James McCluskey; Scott R Burrows; Jamie Rossjohn
Journal:  J Exp Med       Date:  2009-01-12       Impact factor: 14.307

10.  Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion.

Authors:  Danielle Zernich; Anthony W Purcell; Whitney A Macdonald; Lars Kjer-Nielsen; Lauren K Ely; Nihay Laham; Tanya Crockford; Nicole A Mifsud; Mandvi Bharadwaj; Linus Chang; Brian D Tait; Rhonda Holdsworth; Andrew G Brooks; Stephen P Bottomley; Travis Beddoe; Chen Au Peh; Jamie Rossjohn; James McCluskey
Journal:  J Exp Med       Date:  2004-06-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.